Overcoming chemoresistance in triple negative breast cancer
克服三阴性乳腺癌的化疗耐药性
基本信息
- 批准号:10345694
- 负责人:
- 金额:$ 9.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-12-16 至 2022-04-30
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalApoptosisBindingBiological AssayBreastBreast Cancer CellBreast Cancer ModelBreast Cancer PatientBreast Cancer cell lineCRISPR/Cas technologyCell SurvivalCellsCessation of lifeChemoresistanceChemosensitizationClinical DataClustered Regularly Interspaced Short Palindromic RepeatsCollagenCommunicationDNADNA DamageDoseDoxorubicinDrug KineticsExperimental ModelsExtracellular MatrixFibronectinsGenerationsGenesGenetic TranscriptionGoalsHIF1A geneHypoxiaITGA5 geneImmunofluorescence ImmunologicImmunohistochemistryIn VitroInduction of ApoptosisIntegrinsKnock-outLOXL2 geneMammary NeoplasmsMaximum Tolerated DoseMeasuresMediatingMediator of activation proteinMethodsMicroscopyMissionModelingNatureNuclearOrganoidsOutputOxidesPTK2 genePaperPathway interactionsPatient-derived xenograft models of breast cancerPenetrationPharmaceutical PreparationsPharmacodynamicsPharmacotherapyPhenotypePhysiologicalProtein-Lysine 6-OxidaseProteinsProteomicsPublic HealthRefractoryRelapseResistanceRoleSignal InductionSignal TransductionSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationStructure-Activity RelationshipSystemTechniquesTestingTherapeuticToxic effectTranscriptional RegulationUnited States National Institutes of HealthWestern Blottingaggressive breast cancercancer subtypeschemosensitizing agentchemotherapyclinically relevantcrosslinkdisabilityexperimental studyin vivoin vivo ModelinhibitormRNA Expressionmalignant breast neoplasmmortalitymutantnoveloverexpressionoxidationparalogous genepatient derived xenograft modelpatient subsetspharmacokinetics and pharmacodynamicspre-clinicalprotein expressionprototypereconstitutionscreeningsecond harmonicsmall moleculesmall molecule inhibitorstandard of caresuccesstherapy resistantthree dimensional cell culturetraffickingtranscriptome sequencingtranscriptomicstriple-negative invasive breast carcinomatumortumor xenograft
项目摘要
PROJECT SUMMARY
Triple negative breast cancer (TNBC) is the most aggressive breast cancer subtype. It accounts for ~15% of
all breast cancer patients yet is responsible for 30% of breast cancer deaths. TNBC is treated primarily by
conventional chemotherapy; however, resistance to therapy is common leading to high mortality rates.
Recently, we identified hypoxia-induced ECM re-modeler, lysyl oxidase (LOX) as a key mediator of
doxorubicin resistance in TNBC (Saatci et al, Nature Communications, 2020). LOX inhibition offers a unique
opportunity to re-sensitize the most aggressive breast tumors to standard-of-care chemotherapeutics. The
overall objectives of this project are to (i) delineate the roles of LOX in chemoresistance, (ii) determine the
mechanisms through which LOX exerts these roles, (iii) and generate prototypes of potent and selective LOX
inhibitors to overcome chemoresistance in TNBC. We hypothesize that (i) LOX induces resistance not only
to doxorubicin but also to other chemotherapeutic drugs by its enzymatic activity; (ii) LOX exerts this effect
both by increasing collagen cross-linking/fibronectin assembly (canonical LOX function) leading to reduced
drug penetration and increased integrin-mediated signaling and by regulating transcription (non-canonical
LOX function) via interacting and oxidizing its substrates, culminating in activation of FAK/Src signaling and
cell survival; and (iii) targeting LOX activity with selective small-molecule inhibitors will overcome
chemoresistance by blocking both canonical and non-canonical LOX functions in TNBC. These hypotheses
will be tested by pursuing three specific aims: 1) To determine the role of canonical ECM cross-linking function
of LOX in resistance to different chemotherapeutics in TNBC. We will test the general chemosensitizer role
of LOX and necessity of its enzymatic activity by generating cells with CRISPR-mediated LOX knock-out and
reconstitution and testing their effects on chemoresistance in vitro and in vivo. LOX-mediated ECM changes
will be analyzed by advanced microscopy techniques, e.g. MP-SHG, and the resulting drug penetration will
be studied by IF and MALDI-MSI. 2) To determine the role of non-canonical transcription-regulating functions
of LOX in TNBC chemoresistance. We will determine if LOX controls global transcription and identify novel
LOX substrates by combining transcriptomics (RNA-Seq) and proteomics (TurboID) approaches. We will
generate oxidation-deficient LOX substrates and test their effects on LOX-mediated chemoresistance. 3) To
characterize novel LOX enzymatic inhibitors and test their potential as chemosensitizers in TNBC. We will
test the selectivity of our inhibitors in cells with LOX knock-out/reconstitution and their off-target profiles and
test their chemosensitization ability in organoids. We will perform PK/PD and toxicity profiling studies and
test the inhibitors for overcoming chemoresistance in TNBC PDXs. The proposed project is expected to
provide key mechanistic and phenotypic pre-clinical data to show that targeting LOX will overcome
chemoresistance in the most aggressive breast cancer subtype, with a potential to reduce mortality rates.
项目摘要
三阴性乳腺癌(TNBC)是最具侵袭性的乳腺癌亚型。约占15%,
所有的乳腺癌患者仍然负责30%的乳腺癌死亡。TNBC主要通过以下方式治疗:
常规化疗;然而,对治疗的抗性是常见的,导致高死亡率。
最近,我们确定了缺氧诱导的ECM重塑剂赖氨酰氧化酶(LOX)作为缺氧诱导ECM重塑的关键介质。
在TNBC中的阿霉素抗性(Saatci等人,Nature Communications,2020)。LOX抑制提供了独特的
有机会使最具侵袭性的乳腺肿瘤对标准化疗药物重新敏感。的
该项目的总体目标是(i)描述LOX在化学抗性中的作用,(ii)确定
LOX发挥这些作用的机制,(iii)并产生有效和选择性LOX的原型
抑制剂以克服TNBC中的化学抗性。我们假设(i)LOX不仅诱导抗性,
通过其酶活性对多柔比星,但也对其他化疗药物;(ii)LOX发挥这种作用
两者都通过增加胶原蛋白交联/纤连蛋白组装(典型LOX功能)导致降低
药物渗透和增加整合素介导的信号传导,并通过调节转录(非经典
LOX功能)通过相互作用和氧化其底物,最终激活FAK/Src信号传导,
细胞存活;和(iii)用选择性小分子抑制剂靶向LOX活性将克服
通过阻断TNBC中的典型和非典型LOX功能来抑制化疗抗性。这些假设
将通过追求三个具体目标进行测试:1)确定典型ECM交联功能的作用
LOX在TNBC中对不同化疗药物的抗性中的作用。我们将测试一般化疗增敏剂的作用
通过产生具有CRISPR介导的LOX敲除的细胞,
重组并测试它们在体外和体内对化学抗性的作用。LOX介导的ECM变化
将通过先进的显微镜技术(例如MP-SHG)进行分析,并且所产生的药物渗透将
通过IF和MALDI-MSI进行研究。2)确定非典型转录调节功能的作用
LOX在TNBC化疗耐药性中的作用。我们将确定LOX是否控制全局转录并鉴定新的
LOX底物通过结合转录组学(RNA-Seq)和蛋白质组学(TurboID)方法。我们将
产生氧化缺陷LOX底物并测试它们对LOX介导的化学抗性的影响。3)到
表征新型LOX酶抑制剂并测试其作为TNBC化学增敏剂的潜力。我们将
测试我们的抑制剂在具有LOX敲除/重建的细胞中的选择性及其脱靶特征,
测试它们在类器官中的化学增敏能力。我们将进行PK/PD和毒性分析研究,
测试抑制剂用于克服TNBC PDX中的化学抗性。拟议项目预计将
提供关键的机制和表型临床前数据,以表明靶向LOX将克服
最具侵袭性的乳腺癌亚型的化疗耐药性,具有降低死亡率的潜力。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ozgur Sahin其他文献
Ozgur Sahin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ozgur Sahin', 18)}}的其他基金
Developing novel LOX inhibitors to target chemotherapy resistant TNBC
开发新型 LOX 抑制剂以靶向化疗耐药的 TNBC
- 批准号:
10696810 - 财政年份:2023
- 资助金额:
$ 9.25万 - 项目类别:
Inhibiting tumor growth and metastasis in highly aggressive breast cancers with centrosome amplification
通过中心体扩增抑制高度侵袭性乳腺癌的肿瘤生长和转移
- 批准号:
10670436 - 财政年份:2022
- 资助金额:
$ 9.25万 - 项目类别:
Inhibiting tumor growth and metastasis in highly aggressive breast cancers with centrosome amplification
通过中心体扩增抑制高度侵袭性乳腺癌的肿瘤生长和转移
- 批准号:
10621529 - 财政年份:2022
- 资助金额:
$ 9.25万 - 项目类别:
Nanomechanical studies of cells and biomolecules
细胞和生物分子的纳米力学研究
- 批准号:
10406574 - 财政年份:2022
- 资助金额:
$ 9.25万 - 项目类别:
Nanomechanical studies of cells and biomolecules
细胞和生物分子的纳米力学研究
- 批准号:
10668957 - 财政年份:2022
- 资助金额:
$ 9.25万 - 项目类别:
Inhibiting tumor growth and metastasis in highly aggressive breast cancers with centrosome amplification
通过中心体扩增抑制高度侵袭性乳腺癌的肿瘤生长和转移
- 批准号:
10298311 - 财政年份:2021
- 资助金额:
$ 9.25万 - 项目类别:
Overcoming chemoresistance in triple negative breast cancer
克服三阴性乳腺癌的化疗耐药性
- 批准号:
10541879 - 财政年份:2021
- 资助金额:
$ 9.25万 - 项目类别:
Overcoming chemoresistance in triple negative breast cancer
克服三阴性乳腺癌的化疗耐药性
- 批准号:
10642470 - 财政年份:2021
- 资助金额:
$ 9.25万 - 项目类别:
Nanomechanical imaging of protein dynamics via programmable DNA interactions
通过可编程 DNA 相互作用进行蛋白质动力学纳米力学成像
- 批准号:
10020421 - 财政年份:2019
- 资助金额:
$ 9.25万 - 项目类别:
Nanomechanical imaging of protein dynamics via programmable DNA interactions
通过可编程 DNA 相互作用进行蛋白质动力学纳米力学成像
- 批准号:
10217200 - 财政年份:2019
- 资助金额:
$ 9.25万 - 项目类别:
相似国自然基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
- 批准号:LBY21H010001
- 批准年份:2020
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
- 批准号:81703335
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
- 批准号:81670594
- 批准年份:2016
- 资助金额:58.0 万元
- 项目类别:面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
- 批准号:81470791
- 批准年份:2014
- 资助金额:73.0 万元
- 项目类别:面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
- 批准号:81301123
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
- 批准号:81101529
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
- 批准号:39500043
- 批准年份:1995
- 资助金额:9.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Apoptosis regulation by RNA binding proteins
RNA 结合蛋白的细胞凋亡调节
- 批准号:
DDG-2015-00002 - 财政年份:2016
- 资助金额:
$ 9.25万 - 项目类别:
Discovery Development Grant
Apoptosis regulation by RNA binding proteins
RNA 结合蛋白的细胞凋亡调节
- 批准号:
DDG-2015-00002 - 财政年份:2015
- 资助金额:
$ 9.25万 - 项目类别:
Discovery Development Grant
Mechanisms Of RNA-Binding Protein-Mediated Apoptosis In Oral Mucositis
RNA结合蛋白介导的口腔粘膜炎细胞凋亡机制
- 批准号:
9237260 - 财政年份:2013
- 资助金额:
$ 9.25万 - 项目类别:
Mechanisms Of RNA-Binding Protein-Mediated Apoptosis In Oral Mucositis
RNA结合蛋白介导的口腔粘膜炎细胞凋亡机制
- 批准号:
8657030 - 财政年份:2013
- 资助金额:
$ 9.25万 - 项目类别:
Apoptosis regulation by RNA binding proteins
RNA 结合蛋白的细胞凋亡调节
- 批准号:
261206-2009 - 财政年份:2013
- 资助金额:
$ 9.25万 - 项目类别:
Discovery Grants Program - Individual
Mechanisms Of RNA-Binding Protein-Mediated Apoptosis In Oral Mucositis
RNA结合蛋白介导的口腔粘膜炎细胞凋亡机制
- 批准号:
8993725 - 财政年份:2013
- 资助金额:
$ 9.25万 - 项目类别:
Mechanisms Of RNA-Binding Protein-Mediated Apoptosis In Oral Mucositis
RNA结合蛋白介导的口腔粘膜炎细胞凋亡机制
- 批准号:
8503886 - 财政年份:2013
- 资助金额:
$ 9.25万 - 项目类别:
Apoptosis regulation by RNA binding proteins
RNA 结合蛋白的细胞凋亡调节
- 批准号:
261206-2009 - 财政年份:2012
- 资助金额:
$ 9.25万 - 项目类别:
Discovery Grants Program - Individual
Identification of the Insulin-like Growth Factor 2 mRNA Binding Protein (IGF2BP1) as an important regulator of cIAP1 translation and apoptosis in Rhabdomyosarcomas
鉴定胰岛素样生长因子 2 mRNA 结合蛋白 (IGF2BP1) 作为横纹肌肉瘤中 cIAP1 翻译和细胞凋亡的重要调节因子
- 批准号:
269093 - 财政年份:2012
- 资助金额:
$ 9.25万 - 项目类别:
The binding and apoptosis inhibitory action to germ cells of relaxin-like peptide expressed in the boar testis
公猪睾丸表达的松弛素样肽与生殖细胞的结合及凋亡抑制作用
- 批准号:
24580408 - 财政年份:2012
- 资助金额:
$ 9.25万 - 项目类别:
Grant-in-Aid for Scientific Research (C)